Merck Partners with Calla Lily Clinical Care to Advance Novel Intravaginal Drug Delivery Platform
核心洞察
Calla Lily Clinical Care (搜索) and Merck (搜索) have entered a strategic collaboration to develop Callavid (搜索), a leak-resistant intravaginal drug delivery platform designed to address challenges with self-administration of vaginal therapeutics.
The Callavid (搜索) device features a tampon-shaped design with integrated absorbent liner that aims to improve patient experience by reducing concerns around positioning, dosing accuracy, and leakage during vaginal medication administration.
This represents the first industry partnership for the Callavid (搜索) technology, with initial target indications including fertility and pregnancy treatments, and potential applications in oncology (搜索), menopause (搜索), infectious diseases (搜索), and live biotherapeutics.
Calla Lily Clinical Care (搜索), a UK-based women's health-focused medtech company, has announced a strategic collaboration with Merck (搜索) to advance the development of Callavid (搜索), an innovative platform for intravaginal drug delivery. This partnership marks the first industry collaboration for the Callavid technology and represents a significant milestone in addressing longstanding challenges in women's healthcare.
Addressing Critical Unmet Needs in Vaginal Drug Delivery
Callavid (搜索) is designed as a transformational leak-resistant medical device that tackles key challenges associated with self-administration of vaginal therapeutics. Current vaginal drug delivery methods can cause increased patient anxiety related to positioning, dosing accuracy, and concerns around leakage, particularly for therapeutics used in fertility treatments (搜索), oncology (搜索), and hormone therapies (搜索).
The device features a patented leak-free design that delivers vaginal therapeutics using a small, tampon-shaped device combined with an integrated absorbent liner. Callavid (搜索) is engineered for hygienic insertion, remains in place during drug absorption, and can be easily and cleanly removed. This design approach aims to support more consistent drug delivery while reducing patient concerns around leakage and positioning.
Clinical Applications and Target Indications
Initial target indications for Callavid (搜索) include fertility and pregnancy treatments, with the platform showing potential for broader applications across multiple therapeutic areas. The company has identified potential uses in oncology (搜索), menopause (搜索) management, infectious diseases (搜索), and live biotherapeutics delivery.
"This collaboration with Merck (搜索) marks an important milestone in the development of Callavid (搜索), our novel vaginal drug delivery platform," said Thang Vo-Ta, co-founder and CEO of Calla Lily Clinical Care (搜索). "Merck's scientific heritage and forward-looking approach to innovation make them an ideal partner as we work to address long-standing unmet needs in women's health. By improving how vaginal therapeutics are delivered and experienced, Callavid has the potential to enhance both patient outcomes and quality of life."
Strategic Partnership Development
The collaboration builds on initial engagement between the companies through the Merck (搜索) Innovation Challenge in October 2024, which identified alignment around the need for more patient-centric innovation in women's health. Dr. Lara Zibners, co-founder and chairman of Calla Lily Clinical Care (搜索), emphasized the clinical significance of the partnership.
"As both a clinician and a patient, I have seen how profoundly drug delivery can shape treatment experience," Dr. Zibners stated. "This collaboration builds on that early dialogue and reflects a shared interest in rigorously exploring new approaches that may improve how therapies are delivered and experienced by patients."
The partnership aims to translate the Callavid (搜索) technology into real-world clinical and patient impact, with both companies committed to advancing patient-centric solutions in women's healthcare through rigorous development and testing of the innovative delivery platform.